MYGN Share Price Performance
US$3.87
-22.09 (-85.09%)
48.1% undervalued intrinsic discount
US$7.46
Fair Value
Price US$3.87
AnalystConsensusTarget US$7.46
Fair ValueUS$7.46
Share PriceUS$3.87
48.1% undervalued intrinsic discount
MYGN Community Narratives
AN
Fair Value US$7.46 48.1% undervalued intrinsic discount
PATHOMIQ AI Partnership Will Expand Oncology And Women's Health
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
MYGN Community Fair Values
- US$7.46FV48.1% undervalued intrinsic discount4.42%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative13 days ago author updated this narrative
Recent MYGN News & Updates
No updates
Myriad Genetics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.10
- Gross Margin
- 70.01%
- Net Profit Margin
- -12.20%
- Debt/Equity Ratio
- 8.4%
Myriad Genetics, Inc. Competitors
About MYGN
- Founded
- 1991
- Employees
- 2700
- CEO
- WebsiteView website
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
The market has dropped by 21% in the last 7 days, with the Consumer Discretionary sector leading declines. In contrast to the last week, the market is actually up 21% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading